The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Know the risks and potential benefits of clinical studies and talk to your health care provider before participating.
Read our disclaimer for details.

Changes in disability assessed based composite score of EDSS, timed 25 foot walk (T25FW), and nine hole peg test (9HPT) (EDSS-Plus). Improvement will be defined by at least one of the following three measures: ≥0.5 improvement in EDSS, ≥20% improvement in T25FW, and ≥20% improvement in 9HPT in either dominant or non-dominant upper limb. Scores will be compared individually between baseline and post-treatment. Assessments will be made at baseline and 3 months after the 6th treatment/placebo in each crossover group (month 0, 13, and 27).

This is a Phase II, Double-Blind, Placebo-Controlled, Randomized, Cross-over Study designed to determine efficacy of multiple intrathecal administrations of autologous mesenchymal stem cell-derived neural progenitor cells (MSC-NP) compared to placebo in patients with progressive multiple sclerosis. Efficacy will be measured through assessment of disability outcomes. Study participants will receive six intrathecal injections of culture-expanded autologous MSC-NPs at two month intervals in one year and six lumbar punctures as placebo treatment in a second year.

Significant disability shown by an Expanded Disability Status Score (EDSS) of greater than or equal to 3.0, and less than or equal to 6.5, that was not acquired within the last 12 months.

Stable disease state as evidenced by a lack of gadolinium-enhancing lesions on an MRI and by a stable MRI disease burden (number of T2 lesions and size of lesions) in the last six months and no significant change in EDSS (1 point or more) in the last 12 months

Must agree to undergo four MRIs: at the time of enrollment, after year 1, after year 2, and after year 3

Patients either within the geographical area or who are able to arrange reliable travel during the study period

Exclusion Criteria:

EDSS greater than 6.5

Duration of Disease >15 years at time of screening

Change of disease modifying agent < 6 months prior to beginning treatment. Additionally, no changes in disease modifying agent will be made during the course of the study.

Change in MS symptom management treatment < 6 months prior to beginning treatment. Additionally, no changes in MS symptom management treatments will be made during the course of the study, unless there has been clinical improvement, in which case, a patient may discontinue a medication.

Start of any new orthotic device or durable medical equipment < 6 months prior to beginning treatment or during the course of the study (patients may discontinue use of these devices during the course of the study if they show clinical improvement).

All patients who have ever been on Lemtrada (alemtuzumab)

All patients who have had any prior stem cell treatments, including HSCT

Pregnant or nursing mothers, or any woman intending to become pregnant in the next three years

All patients will have screening blood tests done. Only patients whose values are in the normal range as determined by the laboratory norms based on age and sex will be allowed to participate. Exceptions may be made for borderline normal laboratory values manifesting no clinical symptoms at the discretion of the Principal Investigator.

Use of systemic chemotherapeutic or anti-mitotic medications within three months of study start date due to the possibility of interference with bone marrow procedure

Any patients with a history of or with active malignancy

Use of steroids within three months of the study start date, as this would suggest an active disease state

History of cirrhosis due to increased risk of central nervous system (CNS) infection

Significantly uncontrolled hypertension because of increased risk for stroke or CNS hemorrhage.

Patients with active thyroid disease resulting in hyperthyroidism or hypothyroidism (Only well controlled patients with labs in the normal range will be included) because of hormone influence on cell growth

History of central nervous system infection or immunodeficiency syndromes due to increased risk of CNS infection

Any evidence of significant cognitive dysfunction based on a screening history and physical examination because it would preclude giving a truly informed consent

Patients who are enrolled in another clinical trial for MS treatment or who have received any study drug/biologics within the last 6 months. Additionally, while in the trial, patients may not enroll in any other clinical trial for MS or any other condition.

Patients who are anticipated to have difficultly accessing the intrathecal space related to scoliosis, obesity, or any other relevant factors determined by the PI.